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“Our Choice” improves use of safer
conception methods among HIV
serodiscordant couples in Uganda: a cluster
randomized controlled trial evaluating two
implementation approaches
Glenn J. Wagner1*, Rhoda K. Wanyenze2, Jolly Beyeza-Kashesya3, Violet Gwokyalya4, Emily Hurley5,
Deborah Mindry6, Sarah Finocchario-Kessler7, Mastula Nanfuka8, Mahlet G. Tebeka9, Uzaib Saya9, Marika Booth1,
Bonnie Ghosh-Dastidar1, Sebastian Linnemayr1, Vincent S. Staggs5 and Kathy Goggin5

Abstract
Background: Safer conception counseling (SCC) to promote the use of safer conception methods (SCM) is not yet
part of routine family planning or HIV care. Guidelines for the use of SCM have been published, but to date there
are no published controlled evaluations of SCC. Furthermore, it is unknown whether standard methods commonly
used in resource constrained settings to integrate new services would be sufficient, or if enhanced training and
supervision would result in a more efficacious approach to implementing SCC.
Methods: In a hybrid, cluster randomized controlled trial, six HIV clinics were randomly assigned to implement the
SCC intervention Our Choice using either a high (SCC1) or low intensity (SCC2) approach (differentiated by amount
of training and supervision), or existing family planning services (usual care). Three hundred eighty-nine HIV clients
considering childbearing with an HIV-negative partner enrolled. The primary outcome was self-reported use of
appropriate reproductive method (SCM if trying to conceive; modern contraceptives if not) over 12 months or until
pregnancy.
Results: The combined intervention groups used appropriate reproductive methods more than usual care [20.8%
vs. 6.9%; adjusted OR (95% CI)=10.63 (2.79, 40.49)], and SCC1 reported a higher rate than SCC2 [27.1% vs. 14.6%; OR
(95% CI)=4.50 (1.44, 14.01)]. Among those trying to conceive, the intervention arms reported greater accurate use of
SCM compared to usual care [24.1% vs. 0%; OR (95% CI)=91.84 (4.94, 1709.0)], and SCC1 performed better than
SCC2 [34.6% vs. 11.5%; OR (95% CI)=6.43 (1.90, 21.73)]. The arms did not vary on modern contraception use among
those not trying to conceive. A cost of $631 per person was estimated to obtain accurate use of SCM in SCC1,
compared to $1014 in SCC2.
(Continued on next page)
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Conclusions: More intensive provider training and more frequent supervision leads to greater adoption of complex
SCM behaviors and is more cost-effective than the standard low intensity implementation approach.
Trial registration: Clinicaltrials.gov, NCT03167879; date registered May 23, 2017.
Keywords: HIV, Safer conception counseling, Contraception, Family planning, Uganda, Serodiscordant couples, Safer
conception methods, Timed condomless intercourse, Manual self-insemination, Implementation approaches

Contributions to the literature
 This hybrid cluster randomized controlled trial is the first to
examine a multi-level safer conception counseling intervention for HIV serodiscordant couples implemented in the
standard manner used in resource constrained settings vs. a
higher intensity training and supervision approach.

 Findings demonstrated that the implementation approach
with more provider training and more frequent supervision
resulted in greater use of safer conception methods and was
more cost-effective than the standard implementation
approach.

 Regardless of implementation approach, the Our Choice
intervention was more efficacious than usual care,
demonstrating a large magnitude of effect.

 This is the first cost-effectiveness analysis of a multi-level
safer conception counseling intervention and the first to include implementation strategy costs.

 Findings that adequate training and ongoing supervision are
essential in promoting adoption of this complex health
behavior and ultimately more cost-effective addresses gaps
in the literature and may be applicable to the management
of many other chronic illnesses.

Background
Approximately 40% of HIV-infected women in Uganda
become pregnant after HIV diagnosis [1, 2], and roughly
half of these pregnancies are planned [2]. With 60% of
HIV-affected couples in Uganda being serodiscordant
[3], comprehensive family planning (FP) services are
needed to help persons living with HIV (PLHIV) and
their partners make informed childbearing decisions,
and use effective methods for either safely conceiving or
preventing unplanned pregnancies.
Despite FP services being integrated into HIV care,
providers rarely discuss childbearing with clients prior to
pregnancy [4]. HIV risk for serodiscordant couples is
nearly eliminated by effective use of antiretroviral therapy (ART) [5], and while most are on ART [6], over a
third of those on ART have unsuppressed viral load [6],
and few seronegative partners in sub-Saharan Africa
have access to pre-exposure prophylaxis (PrEP) [7, 8].

Safer conception methods (SCM) complement ART in
promotion of safer conception, but knowledge of SCM is
poor [9], and a prior study found that 35% of 400 PLHIV
trying to conceive used SCM [10].
Providers could facilitate an informed childbearing
decision-making process with periodic childbearing discussions. Clients could then be offered contraception to
prevent pregnancy, or safer conception counseling
(SCC) for effective SCM use if trying to conceive. SCC
guidelines for PLHIV exist [11], but have not resulted in
integration of SCC with either FP or HIV care. No randomized controlled trials of SCC were identified in a
2018 systematic review [12]; however, a prospective observational cohort study of 334 couples offered SCC
found that many were able to use SCM to successfully
conceive without any seroconversions [13]. It is also unknown whether the standard approach for integrating
new services commonly used in resource constrained
settings is sufficient to promote use of SCM, or whether
more intensive training and supervision is needed, as
suggested by studies of implementation approaches to
increase complex health behaviors [14].
We conducted a hybrid cluster randomized controlled
trial that compared usual care to two modes of implementing a SCC intervention named Our Choice. The
study had two main objectives: (1) to determine the efficacy of Our Choice versus usual care on the primary
outcome of accurate use of SCM or modern contraceptives consistent with client’s reproductive goal, and (2)
to evaluate high versus low intensity approaches (differentiated by amount of training and frequency of supervision) to implementing Our Choice in terms of effects on
the primary outcome and cost-effectiveness. We hypothesized that Our Choice would result in greater use of the
appropriate reproductive method than usual care, and
the more intensive implementation approach would lead
to better uptake than the less intensive implementation
approach, and be more cost-effective.

Methods
Study design

The study design was a three-arm cluster-randomized
controlled trial conducted at six HIV clinics operated by
The AIDS Support Organization (TASO) across 6 districts of Uganda (Wakiso, Masaka, Mbale, Jinja,
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Rukugiri, Mbarara). A cluster design was used to limit
risks of contamination biases across treatment
conditions.
Randomization and masking

Using a blind manual drawing, clinics were randomly
assigned to one of three conditions by the project director: one of two implementation approaches for integrating SCC into FP services (more intensive=SCC1, less
intensive=SCC2) or usual care (existing FP services). Allocation was neither concealed to providers nor individual participants (although clients did not know if their
clinic was SCC1 or SCC2). The assigned condition was
applied clinic-wide for all clients.
Power analysis With a planned sample size of 400, enrolled evenly across 6 sites, and using an intra-class correlation (ICC) of 0.01 and assumed attrition of 10%
attrition at month 12, our power analysis determined we
would have > 80% power (2-tailed test) to detect a 4.5
percentage point difference (small effect size) for our
comparison of the usual care arm to the combined
SCC1 and SCC2 arms on the primary outcome, and a 7
to 8 percentage point difference between the SCC1 and
SCC2 intervention arms.
Participants completed assessments at baseline, month
6, and month 12. If the client experienced a pregnancy
by month 12, the final study assessment was conducted
approximately 1 month after pregnancy completion. Participants were followed as long as they were still in a relationship with the partner they enrolled with at
baseline; if they separated from this partner mid-study,
the next assessment would be their final, unless they had
an ongoing pregnancy which would lead to an assessment at the completion of that pregnancy. The protocol
was approved by Institutional Review Boards at TASO
and RAND, and described in a prior publication [15].
The research conformed to the principles embodied in
the Declaration of Helsinki. The trial was registered with
the NIH clinical trial registry (clinicaltrials.gov) and
assigned the number NCT03167879.
Patient and public involvement

HIV clients provided input into the intervention development and outcome measures through participation in
prior research that involved piloting the intervention
and formative research including focus groups and indepth interviews. Furthermore, HIV clients who volunteer as “expert clients” at the clinic sites were involved
in aspects of implementing the intervention including
community outreach and childbearing screening. These
same clients will also be involved in dissemination of the
study findings.
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Study setting and participants

TASO is the oldest indigenous non-governmental
organization (NGO) in Uganda providing comprehensive
HIV care. Each site provides care to 6,000-8,000 clients
and has a staff of 15-20 medical providers. Clients were
eligible if they met the following criteria: (1) in a serodiscordant relationship (partner’s HIV-negative status
confirmed by rapid HIV test prior to enrollment), (2) of
reproductive age (men age 15-60 years; women age 1545), (3) considering childbearing with their partner (determined via triage screening item), (4) not currently
pregnant (determined by a pregnancy test prior to enrollment), and (5) reports having disclosed HIV status to
partner. Recruitment was stratified by sex to ensure a
50/50 balance in the overall study enrollment (not by
study arm), and took place between July 2017 and
January 2019. Clients who were potentially eligible were
informed of the study by clinic staff and referred to the
study coordinator for consent procedures. All enrolled
participants provided written informed consent.
Intervention conditions
Our Choice

Informed by our earlier research [10, 16] and guided by an
ecological adaptation of the Information, Motivation and
Behavioral skills (eIMB) model of behavior change [17],
we developed a multi-component, structured intervention
that engages HIV clients and their partners with fertility
desires in SCC. The goal of the Our Choice intervention is
for providers to facilitate an informed childbearing
decision-making process and support each couple’s decision with training on the use of contraception or SCM in
accordance with their reproductive goal. The counseling
not only provides guidance and support for accurate use
of SCM but also helps ensure that couples who opt not to
seek pregnancy receive support to use a modern contraceptive rather than relying solely on condoms which are
often inconsistently used. The intervention components
are as follows: (1) client outreach to increase awareness
and uptake of services, (2) routine screening of childbearing desires at triage, and (3) provision of SCC, starting
with an initial consult conducted by an HIV counselor to
facilitate an informed decision from the couple to pursue
or delay pregnancy, followed by subsequent referral to FP
nurses for either provision of contraception or monthly
SCC sessions (see Supplement Figure 1). The client’s partner was encouraged to attend sessions, if possible. SCC
was implemented by trained FP nurses, using a structured
protocol and manual, the content of which is summarized
in Supplement Table 1.
Low vs. high intensity approaches to implementation

Our Choice was implemented using two approaches,
SCC1 and SCC2; both used the same content, manual
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and tools, but differed on the method, duration, and frequency of training and supervision of FP nurses and
HIV counselors (see Supplement Table 2). SCC1 was the
more intensive approach, with the study team providing
initial training of providers over 2 days and supervision
starting twice-a-month before transitioning to monthly
contact at month 6. SCC2 was less intensive and
followed the standard model used by the Uganda Ministry of Health (MoH) to integrate new services: initial 1
day training and quarterly supervision sessions (although
in reality supervision occurred every 6-9 months) provided by MoH supervisors who had been trained by the
study team.

Measures

Usual care control

Primary outcome

Control sites received no training and provided FP services as usual, with no use of routine screening of childbearing desires or SCC.

The primary outcome was the accurate use of SCM
[timed condomless intercourse (TCI), manual selfinsemination (MSI), sperm washing] or contraception

Assessments included measures of the primary outcome
(see below), secondary outcomes (any use of SCM/
contraception, pregnancy, partner seroconversion), and
sociodemographic, HIV disease, and relationship/partner
characteristics, as well as reproductive history and behaviors (see Table 1). Self-report measures underwent a
translation, back-translation, and group consensus review process in Luganda and Runyakitara (local languages used in the study settings) [18], and were
interviewer-administered using computer-assisted software. All measures were assessed at each assessment
time point.

Table 1 Study measures
Primary outcomes
Use of appropriate reproductive method to achieve
stated reproductive goal (among whole sample)

Client’s self-reported use of accurate SCM (if trying to conceive) or
modern contraceptives (if not trying to conceive), as defined below.

Accurate use of safer conception methods
(among those trying to conceive)

Interviewer-rated criterion-based assessment of client’s self-reported
use of timed condomless intercourse (TCI), manual self-insemination
(MSI), or sperm washing.

Use of modern contraceptives (among those not
trying to conceive)

Client’s self-reported use of modern contraceptives (birth control
pills, medroxyprogesterone acetate injection, intrauterine device,
implant, or tubal ligation/vasectomy).

Secondary outcomes
Any use of SCM (among those trying to conceive)

Client’s self-reported use of the following:
TCI: Did you have condomless or “live” sex only on the 3 days each
month in which you/your partner were/was most fertile?
Sperm washing: Did you/your partner pay for technology that
cleanses your/your partner’s sperm or semen of the HIV virus?
MSI (among female clients): Did you/your partner ejaculate into a
condom or container and then manually inject the semen into your/
partner’s vagina?

Use of any method to prevent pregnancy
(among those not trying to conceive)

Use of modern contraceptives, consistent condom use, or abstinence.

Pregnancy status

Whether or not female partner become pregnant during the study,
confirmed via pregnancy test conducted by FP nurse.

Partner seroconversion

Partner HIV status based on rapid HIV test conducted by clinic staff
at month 12 or at post-pregnancy assessment.

Covariates
Demographics

Age, sex, and education level (whether or not any secondary
education was completed) as self-reported by client.

HIV medical and care characteristics

HIV diagnosis date, ART status, most recent CD4 count and HIV viral
load were abstracted from the clients’ clinic chart.

Relationship/partner characteristics

Marital status, length of relationship, co-habitation with partner,
partner’s age, and whether partner was using HIV pre-exposure
prophylaxis (PrEP), all assessed via client self-report.

Reproductive health history and behaviors

History of respondent or partner having biological children, having a
child together, having been tested for infertility, or a health care
provider ever telling them they may have fertility problems, and
whether either had been diagnosed or (and treated for) a sexually
transmitted infection in the prior 6 months, via client self-report.
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consistent with the client’s reproductive goal. This goal
was determined at follow-up assessments by asking
whether they had tried to conceive a child with their
partner at any time in the past 6 months. Clients with
missing responses were classified as trying to conceive if
they endorsed “currently trying to conceive” at their
most recent prior assessment. To assess accurate use of
SCM, clients were asked in an open-ended format to describe exactly how they implemented their chosen SCM.
Interviewers listened, probed for specific criterion not
spontaneously mentioned, and rated the presence or absence of pre-defined criterion for each SCM (see Supplement Table 3). All criteria needed to be present for
clients to be classified as accurately using the method.
To assess contraception use, clients were asked if they
or their partner were currently using modern contraceptives, condoms, or abstinence to prevent pregnancy.
Male participants were asked to consent to the interviewer calling their partner during the interview to
assess use of contraception (calls were made in private
and responses were not shared with the male partner).
Accurate use of contraception was defined as using a
modern contraceptive (i.e., birth control pills, medroxyprogesterone acetate injection, intrauterine device, implant, tubal ligation/vasectomy); condoms were not
considered to be a modern contraceptive. This definition
is consistent with FP practice in Uganda [19], as condom
use is typically not consistent and therefore not reliable
for preventing pregnancy, and it also requires cooperation from the male partner. We also assessed an alternative or secondary measure of contraception, such that
participants who reported use of either modern contraception, consistent condom use, or abstinence were classified as using contraception.
Data analysis

We conducted initial bivariate analyses to compare
the study arms on baseline measures of sociodemographic characteristics, HIV disease characteristics,
partner/relationship characteristics, and reproductive
health history/behavior for participants. We assessed
differences using chi-square or Fisher’s exact test
(FET) for categorical variables, and two-tailed independent t tests for continuous variables. We repeated
this analysis to compare those who completed the
study with those who dropped out.
The primary analyses followed an intent-to-treat (ITT)
approach (i.e., outcomes with missing data are designated as not engaging in the desired behavior or achieving the desired pregnancy status) and had two main
objectives. First, to examine efficacy of Our Choice, we
examined whether the primary outcome was more
prevalent in the intervention group (SCC1 and SCC2
combined) compared to the usual care group. Second,
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we examined the relative efficacy of the two implementation approaches to administering Our Choice by comparing the effects of the higher intensity SCC1 versus
the lower intensity SCC2. In both analyses, we first
conducted bivariate chi-square or Fisher’s exact tests to
assess associations between the outcome and treatment
condition. We further tested for association using
covariate-adjusted firth logistic regressions [20, 21]. Each
logistic regression was adjusted for these covariates: age,
sex, any secondary education, time since HIV diagnosis,
marital status, length of relationship with partner, and
whether the participant had a child with their partner.
The model included fixed effects for site to account for
clustering and allow for time-invariant differences across
sites (a mixed model approach was not possible for outcomes with quasi-separation or all zero values as was
observed in the usual care arm). We relied on the effect
sizes (estimated by the differences across study arms) as
demonstration of practically meaningful results, although statistical significance and p values were calculated and are presented. Effect sizes were estimated
using Cohen’s d. This same approach was used to examine effects on the secondary outcomes. We replicated all
analyses with study completers only. The results of this
analysis (not presented) were very similar to that of the
ITT analysis.
Cost-effectiveness analysis

We conducted a cost-effectiveness analysis (including
implementation strategy costs [22];) based on program
costs for personnel, supervision, training, and materials
across both active study arms. Personnel costs included
those for counselors, nurses, and expert clients, who
over the course of the study were asked to recall how
much time they spent weekly delivering intervention
activities. Supervision costs were estimated by multiplying the duration of supervision sessions by the respective
supervisor’s hourly salary and number of supervisory
sessions conducted and including any transportation
costs. Training costs included those for the initial trainings for providers (including transport and per diem), as
well as any refresher trainings conducted, and costs incurred for training supervisors. Material costs included
those for brochures, videos, phone top-ups for nurses,
and transport for participants.
To examine the cost-effectiveness of the two different
implementation approaches used in SCC1 and SCC2, we
compared total intervention costs across the two active
study arms for the primary outcome. Because this is one
of the first analysis of SCC in this setting, we also
assessed the costs for accurate use of SCM on its own
among those trying to conceive. The cost-effectiveness
of contraception provision in Uganda has already been
established [23]. Because supervisors in SCC1 were
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research staff with significantly higher salaries than the
MoH supervisors in SCC2, we conducted an additional
more realistic “scale-up scenario” showing the costs of
SCC1 if its supervisors’ salaries were the same as the
MoH supervisors’ salaries. The cost-effectiveness ratio
was calculated as the cost per participant divided by the
relative effect size in that group compared to the usual
care control. Costs in local currency were converted at
3600 Ugandan Shillings=US $1 and reported in 2020
prices adjusted for inflation.

Results
Sample characteristics

In each of the three study arms, 130 clients consented
and enrolled; the partner of one client in the SCC1 arm
tested seropositive during screening, so this client was
administratively removed. Therefore, a total of 389 clients comprise the study sample (129 in SCC1 and 130 in
each of SCC2 and usual care arms). Figure 1 depicts the
flow of participants through the assessment protocol.
Sixteen participants (4.1%) were lost to follow-up either
before the month 6 (n=6) or month 12 (n=10) assessments. Those lost to follow-up were similar to study
completers with respect to baseline characteristics, except participants in SCC1 were more likely to be female
compared to the usual care group (see Table 2). No
harms or unintended negative events attributed to the
intervention were reported, although 16 participants reported separating from their partner.
Fidelity to Our Choice intervention

More participants in SCC1 received the initial safer conception consult [127 (98.4%) vs. 115 (88.5%); FET =
.002] and follow-on SCC or FP services consistent with
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their reproductive goals [116 (89.9%) vs. 94 (72.3%); p=
.001)], compared to SCC2. Among those who decided to
pursue childbearing after the initial consult (n=105 in
SCC1 and 87 in SCC2), 85.7% (n=90) of those in SCC1
received additional SCC sessions [mean (SD) of 3.4 (2.2)
added sessions; median = 3; range 1-9], compared to
64.4% (n=56; p=.001) of those in SCC2 [mean (SD) of
3.0 (1.5) added sessions; median=3; range 1-7]. In SCC1,
91.3% (116/127) of the partners attended the initial safer
conception consult, and 70.0% (63/90) attended at least
one of the successive SCC sessions, while in SCC2,
60.9% (70/115) of partners attended the initial consult
and 58.6% (51/87) attended at least one SCC session. Of
those in SCC1 who received SCC sessions to promote
childbearing, 18.8% (15 of the 80 who provided such
data) never established a stable menstrual pattern to
allow for the use of SCM, and another 30.0% (24/80)
were only able to establish two stable menstrual cycles
which allowed for only one SCM attempt. Comparable
data were not consistently recorded in SCC2.
Intervention effects on primary and secondary outcomes

Table 3 lists the group comparisons on all primary and
secondary outcomes, with and without covariate adjustment, and using an ITT analysis (p values listed in the
text are from the adjusted models).
Intervention effect on use of appropriate reproductive
method

The combined intervention group (SCC1/SCC2) reported a higher rate of accurate SCM use (TCI or MSI;
sperm washing was not reported by anyone) or modern
contraception consistent with their reproductive goal,
compared to the usual care group (20.8% vs. 6.9%; p=

Fig. 1 Consort diagram of study participants. Asterisk denotes 1 participant missed month 6 assessment and returned for month 12. PPT, post
pregnancy completion assessment

195 (50.3%)
132 (33.9%)

Some secondary education

385 (99.2%)

Undetectable HIV viral load (n=315)b

Currently on ART

Time on ART (years)

35.9 (8.1)

344 (88.4%)

195 (50.1%)

Participant has biological children

Has had a child with partner

187 (50.1%)

335 (89.8%)
8 (50.0%)

14 (87.5%)

2 (12.5%)

15 (93.8%)

9.6 (9.5)

14 (87.5%)

8·5 (7.2)

16 (100%)

10 (76.9%)

391 (247)

13.2 (9.7)

6 (37.5%)

8 (50.0%)

34.1 (10.5)

Mean (SD)/n (%)

Lost to follow-up
(n=16)

0.992

0.766

0.543

0.497

0.907

0.682

0.710

0.718

0.487

0.142

0.241

0.758

0.992

0.372

P
value

59 (45.7%)

118 (91.5%)

23 (17.8%)

116 (89.9%)

9.3 (9.6)

113 (87.6%)

7.7 (7.5)

129 (100%)

90 (87.4%)

537 (287)

11.0 (9.1)

34 (26.4%)

78 (60.5%)

35.1 (7.2)

Mean (SD)/n (%)

SCC1 (n=129)

63 (48.5%)

112 (86.2%)

27 (20.8%)

114 (87.7%)

9.4 (11.1)

102 (78.5%)

7.4 (7.0)

128 (98.5%)

78 (78.8%)

535 (319)

9.6 (8.6)

49 (37.7%)

66 (50.8%)

35.3 (8.0)

Mean (SD)/n (%)

SCC2 (n=130)

SD standard deviation, PrEP pre-exposure prophylaxis, SCC1 safer conception counseling (high intensity approach), SCC2 safer conception counseling (low intensity approach)
a
A total of 252 participants had CD4 data available at baseline
b
A total of 315 participants had viral load data available at baseline
c
Among those on ART at baseline

71 (18.3%)
349 (89.7%)

Using modern contraceptives

Reproductive history and behavior
69 (18.5%)

329 (88.2%)

9.9 (10.7)

Currently living with partner

10.0 (10.8)

326 (83.8%)

Length of relationship (years)

312 (83.7%)

7.8 (7.1)

369 (99.2%)

255 (84.2%)

524 (294)

10.6 (8.7)

126 (33.8%)

187 (50.1%)

Married to partner

Partner and relationship characteristics

7.8 (7.1)

265 (83.9%)

CD4 count (cells/mm3)a

c

10.7 (8.7)
518 (293)

Time since HIV diagnosis (years)

HIV disease characteristics

35.9 (8.2)

Female sex

Mean (SD)/n (%)

Mean (SD)/n (%)

Age (years)

Sociodemographic characteristics

Study completers
(n=373)

Total sample
(n=389)

Table 2 Sample characteristics at baseline, by study completion and study arm

0.261
0.220

73 (56.2%)

0.622

0.811

0.363

0.114

0.431

0.368

0.229

0.400

0.191

0.084

0.003

0.095

P value

119 (91.5%)

21 (16.2%)

114 (87.7%)

11.0 (11.3)

111 (85.4%)

8.5 (6.7)

128 (99.2%)

97 (85.1%)

483 (273)

11.5 (8.5)

49 (37.7%)

51 (39.2%)

37.1 (9.1)

Mean (SD)/n (%)

Usual care
(n=130)
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35 (27.1%)

46 (35.7%)

0 (0%)

Secondary outcomes: Used SCM accurately if
trying to conceive or any contraception
(incl condoms) if not trying to conceive

Partner seroconversion to HIV positive at study
endpoint

1 (0.8%)

33 (25.4%)

19 (14.6%)

130

0.320

0.073

0.013

Chi-sq

Sig. test
(unadjusted)

0.94 (0.01-75.66)

3.44* (1.31-9.02)

4.50** (1.44-14.01)

OR (95% CI)

Intervention effect
(covariate adjusted)

36 (34.6%)

Primary outcome: Used TCI or MSI accurately

32 (30.8%)

Became pregnant

29 (33.3%)

1/39 (2.6%)

8/39 (20.5%)

9 (10.3%)

42 (48.3%)

50 (57.5%)

61 (70.1%)

10 (11.5%)

87

0.760

0.152

0.978

0.002

0.025

0.034

0.221

<0.001

61 (31.9%)

0.44 (0.15-1.25)

7 (14.6%)

Primary outcome: Using modern contraceptive

13 (27.1%)
44 (91.7%)

Always use condoms

Did not become pregnant

54 (88.5%)

16 (25.8%)

35 (56.5%)

12 (19.4%)

61

0.589

0.92

0.92

0.487

1.40 (0.17-11.58)

2.78 (0.50-15.63)

1.07 (0.28-4.19)

3.72 (0.37-37.48)

98 (89.9%)

29 (26.6%)

63 (57.8%)

19 (17.4%)

61 (89.7%)

18 (26.5%)

37 (54.4%)

12 (17.6%)

68

27 (31.8%)

0/34 (0%)

0/34 (0%)

0 (0%)

4 (4.7%)

4 (4.7%)

26 (30.6%)

0 (0%)

85

0 (0%)

27 (20.8%)

9 (6.9%)

130

n (%)

Usual care control

0.965

0.984

0.658

0.971

0.902

0.114

0.002

<0.001

<0.001

<0.001

<0.001

<0.001

0.46

0.042

<0.001

Chi-sq

Sig. test
(unadjusted)

0.18 (0.01-4.30)

2.66 (0.57-12.44)

0.52 (0.16-1.75)

1.20 (0.22-6.501)

0.73 (0.25-2.09)

2.77 (0.11-67.26)

9.88 (0.48-201.9)

121.9** (6.30-2360)

424.6** (22.63-7968)

494.4** (26.06-9378)

27.17** (7.84-94.15)

91.84** (4.94-1709)

2.23 (0.02-257.6)

3.63** (1.38-9.61)

10.63** (2.79-40.49)

OR (95% CI)

Intervention effect
(covariate adjusted)

(2021) 16:41

Adjusted models controlled for site, age, sex, education, time since HIV diagnosis, marital status, length of relationship, and whether had child with partner
SCM safer conception method, TCI timed condomless sex, MSI manual self-insemination, SCC1 safer conception counseling implemented with high intensity approach, SCC2 safer conception counseling implemented
with low intensity approach, OR odds ratio, CI confidence interval
**p<0.01
*p<0.05

28 (58.3%)

Using modern contraceptive or always use
condoms or not having sex

Secondary outcomes:

48

n

109

9/108 (8.3%)

22/108 (20.4%)

39 (20.4%)

109 (57.1%)

125 (65.4%)

142 (74.3%)

46 (24.1%)

191

1 (0.4%)

79 (30.5%)

54 (20.8%)

259

n (%)

Intervention
(SCC1/SCC2)

1.13 (0.13-9.54)

1.06 (0.27-4.11)

10.33** (2.60-41.08)

5.12** (1.86-14.50)

4.75** (1.64-13.71)

7.05** (2.07-23.99)

6.43** (1.90-21.73)

Among those not trying to conceive throughout study (n=113) or in one 6-month time period (n=64): total n=177

14/69 (20.3%)
8/69 (11.6%)

Reported accurate TCI

Reported accurate MSI

30 (28.8%)

Reported using TCI

Reported using MSI (among females)

75 (72.1%)
67 (64.4%)

Reported using SCM (TCI/MSI)

81 (77.9%)

Used any (un-named) strategy to reduce risk in
conceiving

Secondary outcomes

104

n

Among those trying to conceive throughout study (n=212) or during one 6-month period (n=64): total n=276

129

n (%)

n (%)

Primary outcome: Used SCM accurately if trying
to conceive or modern contraception if not trying
to conceive

SCC2

SCC1

n

Among all participants in the sample (n=389)

Overall

Table 3 Intention-to-treat comparisons of the primary and secondary outcomes between the combined intervention group and usual care control, and between the two
intervention groups (SCC1 vs. SCC2), with and without covariate adjustment
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.001; Cohen’s d=.38). A similar result (30.5% vs. 20.8%;
p=.04) was found when using the alternative definition
of appropriate contraception (i.e., use of modern contraception, consistent condom use, or sexual abstinence;
see Table 3).
Intervention effects on SCM use among those trying to
conceive

Among the subgroup of 276 participants who reported
trying to conceive throughout the study (n=212) or during one 6-month period (n=64), the combined intervention group reported higher accurate SCM use (24.1%)
compared to the usual care group which had no accurate
use of SCM (p=.002; Cohen’s d=.67). The combined
intervention group also reported higher SCM use in general (regardless of accuracy), as well as higher TCI use,
accurate TCI use, and MSI use (see Table 3). PrEP,
which became available at three of the six sites midway
through the final year of intervention implementation,
was used by just 13 participants.
Among those in the intervention groups who reported
using TCI or MSI, all received calls from the nurse
counselor to inform them when the woman’s most fertile 3-day period was beginning; therefore, the high levels
of inaccuracy for TCI were related to not knowing that
the most fertile period was 3 days (30-43% across both
follow-up assessments), not having condomless sex during the most fertile period (66-76%), and not always
using condoms outside the most fertile period (67-74%).
The inaccuracy of MSI use was mostly due to not knowing that the most fertile period was 3 days (38%), not
injected semen into woman’s vagina during her most
fertile period (69%), the woman not remaining in proper
position for at least 30 min after the injection of semen
(54%), and not always using condoms during sex (46%).
Intervention effects on modern contraception use among
those trying to avoid pregnancy

In the subgroup of 177 participants who reported trying
to avoid pregnancy throughout the study (n=113) or
during one 6-month period (n=64), the combined intervention group (17.4%) demonstrated similar level of use
of modern contraceptives as the usual care group
(17.6%; p=.832). There were also no noteworthy differences when using the alternative definition of modern
contraception, consistent condom use, or abstinence
(see Table 3).
Intervention effects on pregnancy and partner
seroconversion

Among the subgroup of 276 participants who tried to
conceive, the pregnancy rate did not differ between
those in the combined intervention group (31.9%)
compared to the usual care group (31.8%; p=.902). We
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examined bivariate correlates of pregnancy during the
study among the 265 study completers who reported trying to conceive at either of the follow-up assessments
(see Supplement Table 4). Younger woman’s age was
positively associated with having a pregnancy, while either partner having ever been tested for infertility or being told by a healthcare provider that they may have
infertility problems was associated with not having a
pregnancy. Among those who tried to avoid pregnancy,
the proportion who did not get pregnant did not differ
between the combined intervention group (89.9%) and
usual care group (89.7%; p=.289).
Only one partner (in SCC2) tested HIV-positive at
study endpoint. This couple was trying to conceive but
only attended the initial safer conception consultation.
The partner tested positive just before the month 6
follow-up, at which time the participant reported that
his partner was also pregnant and that they had not been
using SCM. The participant, who had been on ART for
over 8 years and was virally suppressed when last tested
(3 months prior to enrollment), reported condomless
sex with his partner at both baseline and month 6.

Effects of high (SCC1) versus low (SCC2) intensity
intervention on primary and secondary outcomes

As shown in Table 3, SCC1 reported a higher rate of
accurate SCM or modern contraceptive use (27.1%) consistent with their reproductive goal, compared to SCC2
(14.6%; p=.010; Cohen’s d=.31). Among those trying to
conceive during the study, SCC1 had a higher rate of
accurate SCM use (34.6% vs. 11.5%; p=.003; Cohen’s d=
.56), as well as higher SCM use in general, accurate TCI
use and TCI use, compared to SCC2; SCC1 had a similar
pregnancy rate as that of SCC2 in this subgroup (30.8%
vs. 33.3%; p=.760). SCC1 and SCC2 did not differ on
contraception use or pregnancy rate, among those trying
to avoid pregnancy.

Cost-effectiveness of SCC1 vs. SCC2

The cost per client for use of appropriate reproductive
methods (SCM or modern contraception, depending on
reproductive goal) ranged from $105-176 across the
“scale-up” and “actual” scenarios in SCC1, and was $78
in SCC2. The cost per client for accurate SCM use
ranged from $130-218 across these scenarios in SCC1
and was $117 in SCC2. The cost-effectiveness ratio (or
the cost per additional person treated to achieve the
outcome) for use of appropriate reproductive method
was $520-871 in SCC1 for the “scale-up” and “actual”
costs scenarios, and $1014 in SCC2. For the accurate
SCM outcome alone, it was $377-631 in SCC1 and
$1014 in SCC2.
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Discussion
In what may be the first randomized controlled trial of a
SCC intervention for PLHIV, Our Choice recipients selfreported greater use of recommended methods for
achieving their reproductive goal, namely, accurate use
of SCM or modern contraceptives, compared to participants who received usual care. Compared to usual care,
Our Choice was most successful in enabling more clients
to accurately use SCM when trying to conceive, but
produced similar rates of self-reported modern contraception use among those not trying to conceive. Furthermore, the approach to implementing Our Choice that
included more intensive training and supervision was
more successful in increasing self-reported accurate
SCM use than the standard implementation approach.
One of the main study objectives was to determine
whether Our Choice was more efficacious than usual
care in helping clients and their partners to accurately
use SCM if they were trying to have a child. For such clients, the intervention’s magnitude of effect was large. Almost no participants in the usual care control group
reported using SCM, which is not surprising given that
SCC has not been integrated into standard FP practices,
and thus awareness is poor [10, 16]. Nearly two-thirds of
intervention participants reported using SCM, with most
couples using TCI. Some also used MSI, which is noteworthy given that our qualitative research found that
couples often resisted this method and were skeptical of
its “unnatural” method of conception [10]. Just over
one-third of those using SCM used the methods accurately, but more than half of these participants (or their
partners) who used SCM exhibited irregular menstrual
cycles that precluded attempting these methods and
may indicate infertility [24, 25]. Future studies that
include women with regular menstrual cycles are
needed to establish better estimates of the true impact of SCC on accurate SCM use. Additionally, studies that examine the rate and any mutable causes of
infertility would help to clarify the clinical value of
widespread dissemination of SCC.
The other main objective of the study was to determine if the more intensive approach was needed to
achieve better results. Our data clearly show that the
high intensity approach (SCC1) resulted in greater reported use of SCM (TCI in particular). One third of
SCC1 participants trying to conceive reported accurate
SCM use, compared to just one tenth of those in SCC2.
These findings may be attributed to the more extensive
training (2 versus 1 day, and inclusion of motivational
interviewing techniques) and once- or twice-monthly
supervision in SCC1 compared to every 6-9 months in
SCC2. Our process data also revealed the greater likelihood of SCC1 participants receiving the initial safer conception consult and follow-on SCC/FP services, as well

Page 10 of 13

as greater partner attendance in sessions, all of which
may be attributable to the enhanced training and supervision. These findings contribute to evidence from implementation science that suggests the importance of
adequate training and ongoing supervision to successfully integrate new services into routine care [14], as well
as the body of literature suggesting that multi-level,
properly implemented interventions are required to produce change in complex behaviors [26–28].
While the lower intensity SCC2 implementation
approach has lower up-front costs and may therefore appear more sustainable, our findings indicate that the resources needed to implement the more intensive SCC1
approach were in fact more cost-effective in both the
“actual” and “scale-up” scenarios. These findings further
support the merits of implementation approaches that
ensure adequate training and ongoing supervision support to providers when attempting to implement a new
service, especially one that involves a complex health behavior like safer conception. We conducted the “scaleup” scenario to provide a more accurate estimate of
what supervision would cost in a real-world application
of the Our Choice program. SCC1 superviors garnered
higher salaries because they were members of the research team who held advanced degrees. They received
training to use standardized procedures and materials
and followed the study protocol for providing technical
assistance and ongoing support to providers, none of
which required their advanced degrees or research training. Nevertheless, future studies should evaluate factors
that predict optimal supervision. Policy evaluations for
whether to integrate SCC into FP services for PLHIV
will likely hinge on the important factors of ART use,
viral suppression, and access to fertility testing. Unlike
our study sample, scenarios where ART is not being
used or HIV is not fully suppressed, and both partners
are fertile, could greatly increase the value of implementing SCC to promote prevention of horizontal transmission and safe conception.
Our Choice did not have any effect on reported use of
contraception among those trying to avoid pregnancy.
The intervention was designed to promote use of modern contraception by helping couples reach a joint informed decision to not seek pregnancy, together with a
referral to the FP nurse for usual care contraception services. The lack of an effect suggests that there was no
added effect of the intervention beyond usual care, and
the need for added components that specifically target
contraception use. The overall reported use of modern
contraception among those trying to avoid pregnancy
was very low (15-20%) compared to the 68% found in a
recent large study of HIV-positive Ugandan women
seeking to prevent pregnancy [29]. However, our sample
is distinct from the sample in that study and the general
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HIV population as our enrollment criteria required participants to report consideration of childbearing with
their partner. While the couple may not yet have been in
a position to pursue pregnancy, some desire to have a
child was likely present, and may have served as a barrier
to contraception use, particularly in the larger context of
cultural pressure to have children [1, 30].
With nearly all participants being on ART, and only
one partner seroconversion taking place during the
study, we were not able to adequately assess the benefits
of using SCM or contraception for preventing horizontal
transmission. However, the context of the one seroconversion case does highlight the value of SCC even in the
context of ART use. This case was within the SCC2
group and in a couple that successfully achieved a desired pregnancy, but that did not attend any counseling
sessions after the initial consult and reported no SCM
use. The seroconversion took place despite the index
participant being on long-term ART and virally suppressed just months prior to baseline. While the added
benefit of SCC for prevention of horizontal HIV transmission may be minimal in the context of ART, this case
reveals that some couples remain vulnerable to transmission through potential missed ART doses and blips in
viremia. If this couple had attended more SCC sessions
and used SCM, the viral transmission may have been
prevented.
The ability of SCC to facilitate knowledge of the
woman’s most fertile period and being able to target
conception behavior to her most fertile days would be
expected to bolster the couple’s chances of achieving a
pregnancy. Nevertheless, our data did not reveal such an
advantage for the intervention participants nor those
using SCM. Regardless of arm, about 30% of clients trying to conceive achieved pregnancy, which is consistent
with the 27% pregnancy rate found in a South African
study of couples receiving SCC [13], but lower than the
43% rate observed in our prior Ugandan observational
study of HIV affected couples [31]. Indicators of potential infertility (present in as much as half of our sample)
were associated with failure to conceive. Both HIV infection and use of ART have been shown to impede fertility
[32, 33], although the degree to which is unclear, as is
the rate of infertility among PLHIV.
There are several limitations to the study worth
noting. No survey data were collected from the
partner of the index participant, except for female
partners of male participants who were briefly interviewed on contraception use. Like other studies of
SCC [13], we relied on self-report data to measure
use of SCM and contraceptives, which render the
data susceptible to social desirability bias; however,
we took several steps to mitigate the potential for
this bias including the following: using research staff
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who were independent from the clinic to administer
surveys, reminding participants that their responses
would not be shared with clinic staff, and asking
participants to describe in their own words the
methods they were using to prevent transmission
during attempts to conceive—this was done before
they were asked any questions about SCM and the
interviewers rated their responses as adherent or not
adherent to SCM procedures. It should also be noted
that use of SCM was not only reported in the surveys but also during monthly SCC sessions with
counselors who often made added calls to the couple
to assist in timing of the fertile period and provided
equipment (e.g., syringes for MSI) to help the couple
implement their selected method. Finally, if socially
desirable responding were operating widely among
study participants, then it would presumably be operating in all groups, so we would have seen participants in the control arm reporting use of SCM as
well and this was not the case.
Other limitations included the lack of blinding in
the assessment and analysis of outcomes, which may
have biased the interviewer’s rating of accuracy of
SCM use, and extent to which group differences
were investigated. Also, the sample was comprised
solely of PLHIV receiving HIV care in an NGO setting. Our findings may not reflect PLHIV who are
not in HIV care and perhaps less likely to be familiar with safer conception and contraception methods
and how to use them. HIV care in a public health
facility may also differ from NGO settings such as
TASO in ways that could impact the reproductive
health services and outcomes, such as the level of
resources and personnel. However, the fact that the
usual care arm reported almost no SCM use suggests
minimal influence of potential advantages of NGO
settings. Furthermore, evaluating the intervention in
serodiscordant couples not using ART, with no infertility issues, could reveal dramatically increased
benefits of SCM use for prevention of horizontal
transmission and successful safe conception.

Conclusions
The results of this novel study provide evidence that the
Our Choice intervention benefits uptake of accurate
SCM use among HIV serodiscordant couples. The efficacy and cost-effectiveness of the high intensity implementation approach highlight the critical need for
adequate training and ongoing supervision to successfully implement SCC and promote accurate use of complex health behaviors. The findings favoring the higher
intensity implementation approach for these complex
behaviors may be applicable for other chronic diseases
where adoption of complex behavioral skills is critical
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for clients’ health. The intervention did not affect
contraception use among those trying to avoid pregnancy, suggesting the need for supplementary efforts to
impact this target behavior. A minority of couples trying
to conceive were successful, including those accurately
using SCM, highlighting the potential role of infertility
in this population and the need for further research in
this area.
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